FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Positive Trial Data on Sleep Apnea Drug

[ Price : $8.95]

Apnimed announces positive topline results from its second pivotal Phase 3 trial of AD109 (aroxybutynin and atomoxetine), a once-d...

FDAs Elsa Hallucinates Confidently: Report

[ Price : $8.95]

Gizmodo reports that FDA employees who have used Elsa told CNN the AI tool makes up reports and hallucinates confidently.

Baxter Recalls Mobile Lift Component

[ Price : $8.95]

Baxter Healthcare recalls (Class 1) a mobile lift component used in several patient lift devices due to the risk of improper attac...

Longer Drug Review Time Means Fewer Approvals: CBO

[ Price : $8.95]

Responding to congressional Democrats, the Congressional Budget Office says a nine-month increase in FDA drug review times would l...

FDA Alert on Baxters Infusion Pump

[ Price : $8.95]

FDA issues an early alert highlighting serious safety concerns with Baxter's Novum IQ large volume infusion pump.

Official Action Indicated Rare in GCP Inspections: Report

[ Price : $8.95]

FDA researchers analyze the results of good clinical practice inspections from 2017 to 2023, finding that less than 1% resulted in...

FDA: Multiple Violations at O3UV

[ Price : $8.95]

FDA warns Grand Ledge, MI-based O3UV about multiple CGMP violations in its illegal production of autohemotherapy devices.

CGMP Violations at Glenmark Unit

[ Price : $8.95]

FDA warns Indias Glenmark Pharmaceuticals about CGMP violations in the production of finished drugs at one of its manufacturing fa...

FDA Rejects Replimune BLA for Melanoma Therapy

[ Price : $8.95]

FDA rejects a Replimune priority-reviewed BLA for its melanoma therapy RP1 (vusolimogene oderparepvec).

FDA Wins as Sarepta Folds and Stops Shipping Elevidys

[ Price : $8.95]

FDA wins the latest round in its regulatory battle against gene therapy maker Sarepta Therapeutics after the company agrees to sto...